CDC Panel Recommends Merck's RSV Vaccine for Infants

TL;DR Summary
The CDC's Advisory Committee on Immunization Practices recommended Merck's RSV monoclonal antibody, Enflonsia, for infants, offering a new preventive option against RSV with safety and efficacy demonstrated, potentially impacting public health significantly.
- RFK Jr.’s vaccine committee advises Merck’s RSV shot for babies NewsNation
- RFK Jr’s vaccine panel recommends new RSV treatment for infants The Guardian
- ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season Merck.com
- RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants CNBC
- ACIP’s New Class Endorses RSV, Talks COVID Medscape
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
90%
326 → 32 words
Want the full story? Read the original article
Read on NewsNation